Saltar para: Posts [1], Pesquisa e Arquivos [2]

http://cyto.blogs.sapo.pt

Espaço de publicação e discussão sobre oncologia. GBM IMMUNOTHERAPY ONCO-VIRUS ONCOLOGY CANCER CHEMOTHERAPY RADIOTHERAPY



Terça-feira, 14.07.15

potential link between inflammation and cancer;

 

Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer; Scrimini S, Pons J, Agustí A, Clemente A, Sallán M, Bauçà J, Soriano J, Cosio B, Lopez M, Crespi C, Sauleda J; Cancer Immunology; Immunotherapy (Jun 2015)

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer (LC). Myeloid-derived suppressor cells (MDSCs) down-regulate the T cell receptor ζ chain (TCR ζ) through L-arginine deprivation and lead to T cell dysfunction and deficient antitumor immunity. We hypothesized that abnormally high levels of MDSCs in COPD patients may alter tumor immunosurveillance.

METHODS We compared the proportion of circulating MDSCs (Lin-HLA-DR-/CD33+/CD11b+) (by flow cytometry), arginase I (ARG I) serum levels (by ELISA), and expression levels of TCR ζ on circulating lymphocytes (by flow cytometry) in 28 patients with LC, 62 subjects with COPD, 41 patients with both LC and COPD, 40 smokers with normal spirometry and 33 non-smoking controls. T cell proliferation assays were performed in a subgroup of participants (CFSE dilution protocol).

RESULTS We found that: (1) circulating MDSCs were up-regulated in COPD and LC patients (with and without COPD); (2) MDSCs expansion was associated with TCR ζ down-regulation in the three groups; (3) in LC patients, these findings were independent of COPD and tobacco smoking exposure; (4) TCR ζ down-regulation correlates with T cell hyporesponsiveness in COPD and LC patients.

CONCLUSIONS These results suggest that tumor immunosurveillance might be impaired in COPD and may contribute to the increased risk of LC reported in these patients.

Autoria e outros dados (tags, etc)

por cyto às 15:23

Terça-feira, 14.07.15

Institute for Clinical Immuno-Oncology Aims to Advance Access to Therapies in Community Setting

 

Institute for Clinical Immuno-Oncology Aims to Advance Access to Therapies in Community Setting

 

The Association of Community Cancer Centers (ACCC) has launched the Institute for Clinical Immuno-Oncology (ICLIO) in order to promote the advancement of access to immuno-oncology therapies, particularly in the community care setting.

To facilitate the adoption of immuno-oncology in the community cancer setting, ICLIO will educate medical professionals on the best practices for integrating immuno-oncology into clinical care, insurance and reimbursement, social work, and patient access to novel treatment options.

Resources for the multidisciplinary team include a monthly e-newsletter, monthly e-courses, the ICLIO Scholars Program, the ICLIO White Paper, and the ICLIO National Education Conference.

RELATED: Immunotherapies Shine at ASCO Annual Meeting

Providers with membership to ACCC, who are estimated to treat over 60% of all patients with cancer, will also have access to ICLIO. 

ICLIO is chaired by Lee S. Schwartzberg, MD, FACP, Chief of the Division of Hematology and Oncology at The West Clinic and Professor of Medicine at the University of Tennessee in Memphis.

Reference

  1. ICLIO: An Institute of ACCC. http://accc-iclio.org/advisory-committee/. Accessed July 13, 2015

Autoria e outros dados (tags, etc)

por cyto às 15:18


Mais sobre mim

foto do autor


Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.

Pesquisar

Pesquisar no Blog  

calendário

Julho 2015

D S T Q Q S S
1234
567891011
12131415161718
19202122232425
262728293031